Kornimate/medical-research-clean huggingface dataset:
computed tomography as the first-choice diagnostics in high pre-test probability of coronary artery disease

Conditions: Coronary Artery Disease

Summary: to evaluate the safety and effectiveness of computed tomography angiography in the diagnostic and therapeutic cycle as the first-choice method of imaging in the diagnosis of patients with a high probability of stable coronary artery disease according to european society of cardiology recommendations.

a prospective, randomized open-label, single center trial to evaluate superiority of angio-ct to a classic coronary angiography (concerning effectiveness and safety) in the diagnosis of stable coronary artery disease in patients with indications for invasive coronary angiography.

Eligibility criteria:
inclusion criteria: 1. age \>18 years 2. patients providing written informed consent 3. indications for elective invasive coronary angiography defined by european society of cardiology as: * left ventricle ejection fraction \<50% and typical angina symptoms, * probability of coronary artery disease due to criteria of age, sex and symptoms \>85%, or * probability of coronary artery disease due to criteria of age, sex and symptoms 50-85% with positive or moderate cardiac stress test. exclusion criteria: 1. no consent to the study 2. acute coronary syndrome 3. recurrence of typical angina symptoms 1 year after the last percutaneous coronary revascularization, 4. contraindications to invasive coronary angiography 5. gfr \<60 ml/min/1.73m2 6. significant arrhythmia 7. bmi \>35 kg/m2
safety and efficacy of neuroflo in 8-24 hour stroke patients

Conditions: Cerebrovascular Accident

Summary: the purpose of this study is to assess the safety and feasibility of the neuroflo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment. the neuroflo device is intended to increase blood flow to the brain and potentially reduce the damage caused by stroke.

the study is a prospective, single arm treatment feasibility trial to determine the baseline safety and feasibility of the neuroflo device in acute ischemic stroke patients whose last known time symptom-free is between 8-24 hours. a maximum of 25 patients at 5 us sites and 25 patients at 10 canadian \& european sites may be enrolled in this initial study phase. an independent data safety and monitoring board will assess the safety of the treatment on a routine basis.

Eligibility criteria:
inclusion criteria: * ischemic stroke * nihss between 4-20 * time from symptom onset between 8 and 24 hours exclusion criteria: * hemorrhagic stroke * certain types of heart disease * kidney disease * other conditions the doctor will assess

Keywords: acute ischemic stroke device treatment
evaluation of bone metabolism biomarkers in periodontal diseases

Conditions: Periodontal Diseases

Summary: this study evaluates the levels of biomarkers associated with bone metabolism in patients with different periodontal conditions.

background: in this study, the levels of bone metabolism markers found in the saliva of individuals with different periodontal conditions were compared and the relationship of these markers with periodontal status was examined. method: a total of 60 individuals, 20 with periodontitis (p), 20 with gingivitis (g), and 20 with periodontal healthy (s), were included in the study. periodontal clinical parameters (plaque index, gingival index, bleeding on probing, clinical attachment level and probing pocket depth) and saliva samples were obtained from the individuals. bone metabolism biomarker (necrotizing factor (tnf)-α, osteoprotegerin (opg), nuclear factor kappa-β receptor activator ligand (rankl) and sclerostin) levels in saliva samples were evaluated by enzyme-linked immunosorbent assay (elisa).

Eligibility criteria:
inclusion criteria: * 18-65 years old. * not having any systemic disease that may affect periodontal status * not smoking and alcohol use * volunteer to participate in the study exclusion criteria: * periapical pathologies; * resulting from orthodontics and occlusion extreme forces, including mechanical forces; * chronic high-dose steroid therapy; * radiation or immunosuppressive therapy; * pregnancy; * breastfeeding; * allergy or sensitivity to any medication. * periodontal therapy or drug therapy for at least 6 months of study participants

Keywords: periodontitis saliva sclerostin
af ablation with the ablation index

Conditions: Atrial Fibrillation

Summary: this is an observational multicenter registry of atrial fibrillation catheter ablation performed using the ablation index technology.

this is an observational multicenter registry of atrial fibrillation catheter ablation performed using the ablation index technology, which has been introduced as a tool predicting ablation lesion depth. the index incorporates the following characteristics of radiofrequency point-by-point ablation: radiofrequency energy power, contact force, duration of ablation. since the ablation index is calculated for every individual operator depending on his(her) personal skills, there is no a strict indication on the safe and effective range of the index. this registry aims to evaluate ablation index values used in different centers by different operators. prospective information on arrhythmia recurrence rate and type, characteristics of redo ablations, characteristics of reconduction ablated areas will be gathered.

Eligibility criteria:
inclusion criteria: * indications for catheter ablation of atrial fibrillation; * signed informed consent exclusion criteria: * presence of contraindications to af ablation
treatment of melasma with jessner's solution vs. trichloroacetic acid

Conditions: Melasma

Summary: melasma is an acquired discoloration of the skin characterized by brown patches. chemical peels using agents such as jessner's solution and trichloroacetic acid (tca) are commonly used to treat melasma. a chemical peel involves applying the peeling agent to the skin for a short period. the skin will peel similar to a sunburn, and moisturizers are applied to the skin. although both agents are well-accepted, there have been no good comparisons of the two agents. the purpose of this study is determine if there is a difference in the effectiveness of these two agents.


Eligibility criteria:
inclusion criteria: * adults \> 18 years old * clinical diagnosis of melasma * mental capacity to give informed consent exclusion criteria: * pregnancy * h/o allergy to jessner's solution, tricholoracetetic acid, tretinoin, or hydroquinone * active dermatitis * presence of cutaneous infection

Keywords: melasma jessner's solution trichloroacetic acid (tca)
a bioequivalence study comparing a single 1.5ml dose of brodalumab vs. two doses (1.0ml + 0.5ml) of brodalumab

Conditions: Psoriasis

Summary: a healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single dose of brodalumab vs. two doses of brodalumab

a healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single 1.5ml dose of brodalumab (140mg/ml) vs. two doses (1.0ml + 0.5ml) of brodalumab (140mg/ml)

Eligibility criteria:
inclusion criteria: * healthy males and females with a bmi between 18.0 and 30.0 kg/m2, inclusive. females must be of non-reproductive potential exclusion criteria: * no history or evidence of clinically significant disorder that would pose a risk to subject safety or interfere with study evaluation, procedures, or completion.
respiratory viral infections during acute myeloid leukemia (aml)chemotherapy related aplasia

Conditions: Acute Myeloid Leukemia

Summary: infectious morbidity and mortality is a major complication of aml (acute myeloid leukemia) induction and consolidation chemotherapies related aplasia. the main aim of this study is to measure incidence of respiratory viral infections during aml induction and consolidation chemotherapy related aplasia. primary end point is a positive polymerase chain reaction(pcr)associated with clinical signs.

bacterial and fungal infection treatment is well defined with guidelines. few data are available for viral infections and concern essentially allogeneic stem cell transplantation. these infections are associated with a high mortality and morbidity rate. data concerning aml are essentially retrospective, pediatric and with a little number of patients. respiratory viral infections incidence is not known. these infections may be responsible for a higher mortality rate. different risk factors are found: age superior to 65 years, lymphopenia, co-infections. treatment is subject to a controversy: surveillance or starting an antiviral therapy. this study aims at understanding viral infections epidemiology during long term aplasia and optimizing their management.

Eligibility criteria:
inclusion criteria: * patients over 18 years old with an aml diagnostic and treated with induction and consolidation chemotherapy. patients enrolled in another protocol may be included. * patients with relapsed leukemia who are treated with a salvage intensive therapy stay in the study * patients who have signed a consent policyholder exclusion criteria: * patients under 18 years old * patients treated with another treatment than induction and consolidation chemotherapy * pregnant women * patients hiv, hbv or hbc positive * patients with a positive pcr at j1 * patients treated with an antiviral treatment or an immunosuppressive treatment for another pathology * patients under guardianship * primitive immunity deficit

Keywords: acute myeloid leukemia
the cascade project

Conditions: Cancer

Summary: people with cancer, treated for cancer, or have been recently treated for cancer are at a higher risk of becoming rapidly unwell. this is referred to as an oncological emergency and can be life-threatening. the investigators want to see if a new, standardised assessment of acute oncology knowledge and skills of all health care staff (the acute oncology passport) following education and training, has an effect on the diagnosis and treatment of two relatively-common oncological emergencies: sepsis and mscc? sepsis is blood poisoning, which causes serious injuries if it is not diagnosed and treated as an emergency and may result in death if not treated quickly enough. mscc is metastatic spinal cord compression, where the cancer presses on the spinal cord and can cause permanent paralysis. the investigators have chosen these two conditions, not only because of how serious and relatively common they are for people living with cancer, but also because all nhs trusts in the uk routinely collect and report standardised data about patients who are admitted with suspected sepsis or mscc. the investigators plan to compare data that is routinely collected about the diagnosis and treatment of patients with suspected sepsis and mscc before and after education, training and assessment of staff about acute oncology. the investigators will conduct 'secondary analysis' on the data, as it was originally collected for another purpose. the routinely data collected at five hospital trusts across the uk from 1st april 2023 to 30th june 2023 and 1st october to 31st december 2023 will be included in this study. this research is part of a larger uk-wide project, funded until march 2024 by nhs england workforce, training and education directorate. if acute oncology education, training and assessment of staff is shown to make a difference to patient diagnosis and treatment, the acute oncology passports will be rolled-out nationally.


Eligibility criteria:
inclusion criteria: * all patient kpi's of interest that occur in the study time frame will be collected. exclusion criteria: * kpi data collected from people under the age of 18 kpi data other than items stated in this application, i.e. data that is not reporting neutropenic sepsis nor mscc outcomes
furosemide as supportive therapy for covid-19 respiratory failure

Conditions: Covid19; Respiratory Failure

Summary: this double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study the utility of nebulized furosemide for pulmonary inflammation in intubated, mechanically ventilated patients with covid-19.

this double-blind, placebo-controlled, randomized, parallel-group phase 2/3 study will study the utility of nebulized furosemide for pulmonary inflammation in intubated, mechanically ventilated patients with covid-19. the primary objective of the study is to establish the efficacy and safety of nebulized furosemide for the treatment of respiratory failure secondary to covid-19 infection requiring invasive mechanical ventilation. the secondary objective is to delineate the anti-inflammatory properties of furosemide in covid- 19 patients using pharmacokinetic / pharmacodynamic analysis. the duration of the intervention will be up to 28 days of intervention and patients will be followed till 60 days post randomization. participants will be randomized to either: intervention group: 40 mg furosemide per dose, given by nebulization (4 ml of 10 mg/ml furosemide in 0.9% saline solution) over 30 mins four times daily (q6h) for up to 28 days or control group: placebo, given by nebulization (4 ml of 0.9% saline solution) over 30 mins four times daily for up to 28 days. one hundred and forty-four (144) evaluable patients will be enrolled in the phase 2 study. if evidence of efficacy is found in the phase 2 portion, these patients will be enrolled in the phase 3 study which aims to recruit 640 patients total (496 additional patients to the phase 2 patients).

Eligibility criteria:
inclusion criteria: 1. subjects with respiratory failure secondary to covid-19 (sars-cov-2) infection/pneumonia requiring invasive mechanical ventilation 2. duration of mechanical ventilation less than 48 hours as measured from the time of randomization 3. if female, must not be pregnant at the time of enrollment as determined by a serum or urine pregnancy test exclusion criteria: 1. known history of severe chronic pulmonary disease (e.g., preinfection requirement for home oxygen therapy or presence of chronic hypercapnia (paco2\< 50 mm hg); mild -moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy) 2. in the opinion of the pi, unlikely to survive for \>48 hours from time of enrollment 3. enrollment in another trial of anti-inflammatory therapies for covid-19. 4. known allergy to furosemide or sulfonamide agents
diagnostic accuracy of doppler resistive indices for early diagnosis of acute kidney injury .

Conditions: Cardiac Surgical Procedures

Summary: to determine if ultrasound measurement of renal and carotid arterial resistive indices are associated with post-cardiac surgery acute kidney injury.

to determine if ultrasound measurement of renal and carotid arterial resistive indices are associated with post-cardiac surgery acute kidney injury.

Eligibility criteria:
inclusion criteria: * adult patients \>= 18 years * undergoing cardiac surgery with cardiopulmonary bypass and transesophageal echocardiography (tee) probe placement exclusion criteria: * chronic kidney diseases (estimated gfr \< 60 ml/min/1.73m2) * prior carotid endarterectomy * known carotid artery stenosis of 50% or greater * dissection or aneurysm involving renal or carotid arteries * scheduled aortic or aortic valve surgery * heart transplant * intraaortic balloon pump, ventricular assist device, or exctracorporeal membrane oxygenation support.
study of iguratimod in sjögren's syndrome

Conditions: Sjogren's Syndrome

Summary: a single-center, self-control, open-label study of efficacy and safety of iguratimod in patients with sjögren's syndrome

in this study, patients with sjögren's syndrome are enrolled and received iguratimod 25 mg twice a day for 24 weeks. the differences of esspri (eular sjogren's syndrome patient reported index) score, esspri(eular sjogren's syndrome patient reported index) score, unstimulated salivary flow rate, schirmer's test sf-36 score and haq score between baseline and week 24 are evaluated to determine the efficacy of iguratimod in patients with sjögren's syndrome.

Eligibility criteria:
inclusion criteria: * a diagnosis of sjogren's syndrome according to the revised american-european consensus group (aecg) criteria * positive dry eyes and (or) dry mouth symptoms * hyperglobulinemia exclusion criteria: * complicated with other systemic autoimmune diseases * severe complications of sjogren's syndrome * glucocorticosteroid therapy, systemic immunosuppressant therapy, or biological agents therapy within 3 months prior to the screening visit * active infections or chronic infectious diseases * a history of malignancies * pregnancy or breathfeeding * inability to comply with the study protocol for any other reason

Keywords: sjogren's syndrome iguratimod
value of radiological follow up in children hospitalized with lobar pneumonia

Conditions: Pneumonia

Summary: the study intends to assess the utility of performing a follow up x rays in children admitted to pediatric wards with lobar pneumonia. usually those children are discharged with a recommendation for a follow up x rays but there are no enough studies proving that this recommendation is really necessary.

thew study will include follow up data in a group of about 200 patients admitted with lobar pneumonia during the years 2006 to 2007. all the clinical and laboratory data will be collected and also the x rays findings. the findings of follow up x rays if they were performed will also be summarized.

Eligibility criteria:
inclusion criteria: all pediatric patients discharged with the diagnosis of lobar pneumonia. exclusion criteria: patients with diagnosis of chronic diseases.

Keywords: x rays findings
trabeculectomy with ologen

Conditions: Glaucoma

Summary: trabeculectomy is the gold standard procedure for the surgical treatment of glaucoma. antimetabolites such as mitomycin-c (mmc)are widely used as an adjunctive during surgery to prevent scarring of the bleb. mmc has the risk for creating thin bleb walls, avascular blebs, and increased risk to infection, blebitis and endophthalmitis. recently, a biodegradable porous collagen-glycosaminoglycan copolymer matrix implant (ologen), has become available for glaucoma surgery.although a few studies on filtering surgery with ologen implantation have been performed, there is yet no conclusive evidence on effectivity and safety with ologen implantation when compared to trabeculectomy with mmc. this is a prospective intervention pilot study to determine the degree of intraocular pressure (iop) lowering of trabeculectomy with ologen implantation in comparison to trabeculectomy with mmc. additionally, the safety (per- and postoperative complications) of the two procedures will be compared. the study hypothesis is that trabeculectomy with ologen will be a safer procedure than trabeculectomy with mmc, but probably at the cost of a less potent iop lowering.


Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma with progression of visual field loss and/or uncontrolled intraocular pressure levels with medication. * indication for trabeculectomy with mitomycin-c exclusion criteria: * unability to discontinue oral anticoagulants * difficulty in reading or speaking dutch * previous ocular surgery (cataract surgery allowed) * pregnant and breastfeeding women

Keywords: intraocular pressure glaucoma trabeculectomy ologen
dynamic arterial elastance to predict postural change induced hypotension

Conditions: Hypotension

Summary: during general anesthesia, hypotension might occur during positional change. it is reported that hypotension after positional change from supine to prone is mainly caused by the decrease in preload. the investigators aimed to investigate whether dynamic arterial elastance might predict hypotension associated with positional change from supine to prone.


Eligibility criteria:
inclusion criteria: * patients planned for invasive arterial catheter insertion, undergoing elective spine surgery in prone position under general anesthesia exclusion criteria: * arrythmia * pulmonary disease * increased intracranial pressure * decreased cardiac function (ejection fraction \< 50%) * obesity (body mass index \> 40)
fractional flow reserve and instantaneous free-wave ratio revascularization strategies in women

Conditions: Coronary Disease; Percutaneous Coronary Intervention; Exercise Test; Myocardial Perfusion Imaging; Cardiac Catheterization

Summary: a real world study to evaluate outcomes in women based on guideline identified fractional flow reserve (ffr) and instantaneous wave-free ratio (ifr) cutoffs for ischemia (ischemia defined as ffr ≤ 0.80 and ifr ≤ 0.89).

the women first (ffr ifr revascularization strategies trial) study collects information from enrolled subjects to create a data repository. the data will be used to further elucidate recommendations for pci of angiographically intermediate lesions (30-90% stenosis) in epicardial lesions in women by comparing ffr and ifr findings to findings of inducible ischemia on existing non-invasive stress imaging studies. gender comparisons will also be made from archived and published research data sets from studies comprised up to 80% men. data will also be stored long term for use in future undefined analyses.

Eligibility criteria:
inclusion criteria: 1. female ≥ 18 years old at signing of informed consent 2. suspected myocardial ischemia or acute coronary syndrome 3. indication for non-invasive perfusion imaging study 4. indication for diagnostic catheterization 5. eligible for pci 6. signed informed clinical procedural consent by subject or by surrogate exclusion criteria: 1. inability to receive adenosine or regadenoson (for example, severe reactive airway disease, marked hypotension, or advanced atrioventricular block without pacemaker. 2. severe cardiomyopathy (ejection fraction \<30%) 3. extremely tortuous or calcified coronary arteries precluding ffr/ifr measurements 4. patients with left main coronary artery disease requiring revascularization 5. female of child baring age should have negative pregnancy test 6. subject is pregnant or breast feeding, or planning to become pregnant 7. contraindication to non-invasive stress imaging including severe claustrophobia, renal disease with gfr \<30 where cmr is indication, any metal in the body which is a contraindication to cmr, allergy to gadolinium contrast 8. icd or ppm

Keywords: women first ffr in women ifr in women